Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

in response to

Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

tada

posted on Nov 22, 2018 05:53PM

"I believe 3694 have already been tested in conjunction with Apalutamide however I can't find anything in print so take it for what it's worth."

I wouldn't be surprised if ZEN-3694 has been tested in cancer cell lines with apalutamide. If you recall, they've shown a slide in various presentations summarizing the synergy of ZEN-3694 with various drugs in various cancer cell lines. However, enzalutamide and abiraterone are the only drugs tested in combo with ZEN-3694 in patients according to clinical trial listings and corporate presentations. Enzalutamide and apalutamide are both non-steroidal anti-androgens that antagonize the androgen receptor. So any synergy with enzalutamide I would expect to also occur with apalutamide. Soon the Pfizer PARP inhibitor will begin trials in combo with ZEN-3694 for breast cancer.